EUCTR2006-001173-14-IT进行中（未招募）不适用
Protocol H3E-MC-JMHO(a)A Randomized Phase 3 Trial of ALIMTA (Pemetrexed)and Carboplatin versus Etoposide and Carboplatin inExtensive-Stage Small Cell Lung Cancer - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ELI LILLY
- 入组人数
- 1,770
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Histological or cytological diagnosis of ED-SCLC, including
- •malignant pleural effusion.
- •[2] Performance status of 0 to 2 on the ECOG performance status
- •schedule (Oken et al. 1982). (See Protocol Attachment JMHO.3)
- •[3] No prior systemic chemotherapy, immunotherapy, or biological
- •therapy for SCLC.
- •[4] Prior radiation therapy allowed to <25% of the bone marrow. Patients
- •who have received prior radiation to the whole pelvis or chest for the
- •treatment of SCLC are not eligible. Prior radiotherapy must be
- •completed at least 2 weeks before study enrollment. Patients must
- •have recovered from the acute toxic effects of the treatment prior to
- •study enrollment.
- •[5] At least one unidimensionally measurable lesion meeting Response
- •Evaluation Criteria in Solid Tumors (RECIST; Therasse et al. 2000).
- •A measurable lesion is defined as a lesion that can be accurately
- •measured in at least one dimension and is >=20 mm with conventional
- •techniques or is >=10 mm with spiral computed tomography (CT) scan
- •(longest diameter to be recorded).
- •Positron emission tomography (PET) scans and ultrasounds may not
- •be used for lesion measurements (see Protocol Attachment JMHO.5).
- •Pemetrexed H3E-MC-JMHO(a) Approved by Lilly: 13 April 2006
- •Confidential
- •[6] Adequate organ function including the following:
- •Adequate bone marrow reserve: absolute neutrophil (segmented and
- •bands) count (ANC) >=1.5 x 109/L, platelets >=100 x 109/L, and
- •hemoglobin >=9 g/dL.
- •Hepatic: bilirubin <=1.5 times the upper limit of normal (ULN), alkaline
- •phosphatase (AP), alanine transaminase (ALT) and aspartate transaminase
- •(AST) <=3.0 x ULN (AP, AST, and ALT <=5 x ULN is acceptable if liver
- •has tumor involvement).
- •Renal: calculated creatinine clearance (CrCl) >=45 mL/min based on the
- •standard Cockcroft and Gault formula (Cockcroft and Gault 1976). (See
- •Protocol Attachment JMHO.6)
- •[7] Estimated life expectancy of at least 12 weeks.
- •[8] For women: Must be surgically sterile, post-menopausal, or compliant
- •with a medically approved contraceptive regimen (for example,
- •intrauterine device [IUD], birth control pills, or barrier device) during
- •and for 6 months after the treatment period; must have a negative
- •serum or urine pregnancy test within 7 days before study enrollment,
- •and must not be breast-feeding.
- •For men: Must be surgically sterile or compliant with a contraceptive
- •regimen during and for 6 months after the treatment period.
- •[9] Patient compliance and geographic proximity that allow adequate
- •[10] Patient or his/her legal representative must sign an informed consent
- •[11] Patients must be at least 18 years of age.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- 另有 1 项未显示
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •[12] Have received treatment within the last 30 days with a drug that has
- •not received regulatory approval for any indication at the time of study
- •[13] Have previously participated in a study involving pemetrexed.
- •[14] Have a mixed histological diagnosis of SCLC and NSCLC.
- •[15] Have a serious concomitant systemic disorder that, in the opinion of
- •the investigator, would compromise the patient's ability to adhere to
- •the protocol.
- •Pemetrexed H3E-MC-JMHO(a) Approved by Lilly: 13 April 2006
- •Confidential
- •[16] Have an active infection (>=38.5?C and/or receiving intravenous
- •antibiotic therapy).
- •[17] Have a serious cardiac condition, such as myocardial infarction within
- •6 months, angina, or heart disease as defined by the New York Heart
- •Association Class III or IV (Protocol Attachment JMHO.8).
- •[18] Have had recent (within 30 days of study treatment) or concurrent
- •yellow fever vaccination.
- •[19] Have had a prior malignancy other than SCLC, carcinoma in situ of
- •the cervix, or nonmelanoma skin cancer, unless that prior malignancy
- •was diagnosed and definitively treated at least 5 years previously with
- •no subsequent evidence of recurrence. Patients with a history of low
- •grade (Gleason score <=6) localized prostate cancer will be eligible
- •even if diagnosed less than 5 years previously.
- •[20] Symptomatic central nervous system (CNS) metastases and
- •asymptomatic CNS metastases requiring concurrent corticosteroid
- •therapy. Treated stable CNS metastases are allowed; the patient must
- •be stable after radiotherapy for >=2 weeks and off of corticosteroids for
- •>=1 week.
- •[21] Presence of clinically significant third-space fluid collections, for
- •example, ascites or pleural effusions that cannot be controlled by
- •drainage or other procedures prior to study entry.
- •[22] Significant weight loss (that is, >=10%) over the 6 week period prior to
- •study entry.
- •[23] Concurrent administration of any other antitumor therapy.
- •[24] Inability to interrupt aspirin or other nonsteroidal anti-inflammatory
- •agents, other than an aspirin dose <=1.3 grams per day, for a 5-day
- •period (8-day period for long-acting agents, such as piroxicam).
- •[25] Inability or unwillingness to take folic acid or vitamin B12
- •supplementation.
- •[26] Inability to take corticosteroids.
研究者
相似试验
进行中（未招募）
1 期
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5)CTIS2022-501106-35-00Eli Lilly & Co.700
已完成
3 期
asmiditan study on patients Over Four Migraine AttacksCTRI/2019/05/019167Eli Lilly and Company India Pvt Ltd66
已完成
1 期
se of h-R3 monoclonal antibody and radiotherapy to treat patients with advanced epithelial head and neck tumors.Advanced epithelial head and neck tumors.Head and Neck NeoplasmsNeoplasms, Glandular and EpithelialRPCEC00000071Center of Molecular Immunology (CIM)12
进行中（未招募）
3 期
JCOG1703: A multicenter randomized phase III study for newly-diagnosed maximally resected glioblastoma comparing Carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy aloneglioblastomaJPRN-jRCT1031190035KUMABE Toshihiro250
招募中
3 期
Randomized phase III study for unresectable WHO Grade II diffuse astrocytoma with radiotherapy alone or chemoradiotherapy with temozolomide(JCOG1303, DARTS (Phase-III))WHO Grade II diffuse astrocytomaJPRN-UMIN000014578Japan Clinical Oncology Group (JCOG)260